CN101484162A - 包含抗真菌试剂的组合制剂的用途 - Google Patents

包含抗真菌试剂的组合制剂的用途 Download PDF

Info

Publication number
CN101484162A
CN101484162A CNA200780025026XA CN200780025026A CN101484162A CN 101484162 A CN101484162 A CN 101484162A CN A200780025026X A CNA200780025026X A CN A200780025026XA CN 200780025026 A CN200780025026 A CN 200780025026A CN 101484162 A CN101484162 A CN 101484162A
Authority
CN
China
Prior art keywords
treatment
epithelial
candida
clotrimazole
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780025026XA
Other languages
English (en)
Chinese (zh)
Inventor
C·诺埃
马里昂·诺埃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMACON-FORSCHUNG und BERATUNG GmbH
Original Assignee
PHARMACON-FORSCHUNG und BERATUNG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMACON-FORSCHUNG und BERATUNG GmbH filed Critical PHARMACON-FORSCHUNG und BERATUNG GmbH
Publication of CN101484162A publication Critical patent/CN101484162A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA200780025026XA 2006-05-12 2007-05-10 包含抗真菌试剂的组合制剂的用途 Pending CN101484162A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA826/2006 2006-05-12
AT8262006 2006-05-12

Publications (1)

Publication Number Publication Date
CN101484162A true CN101484162A (zh) 2009-07-15

Family

ID=37903545

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780025026XA Pending CN101484162A (zh) 2006-05-12 2007-05-10 包含抗真菌试剂的组合制剂的用途

Country Status (19)

Country Link
US (2) US8552042B2 (https=)
EP (2) EP2018164B1 (https=)
JP (1) JP2009536926A (https=)
CN (1) CN101484162A (https=)
AU (1) AU2007250502B2 (https=)
CA (1) CA2651726C (https=)
CY (1) CY1119094T1 (https=)
DK (1) DK2018164T3 (https=)
ES (1) ES2627268T3 (https=)
HR (1) HRP20170793T1 (https=)
HU (1) HUE033499T2 (https=)
LT (1) LT2018164T (https=)
NO (2) NO342103B1 (https=)
PL (1) PL2018164T3 (https=)
PT (1) PT2018164T (https=)
RS (1) RS56044B1 (https=)
RU (1) RU2008148977A (https=)
SI (1) SI2018164T1 (https=)
WO (1) WO2007131253A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210649A (zh) * 2010-04-09 2011-10-12 上海医药科技发展有限公司 一种两性霉素b乳膏及其制备方法
CN107106690A (zh) * 2015-01-13 2017-08-29 方济各安吉利克化学联合股份有限公司 用于治疗真菌病的药物组合物
CN111601585A (zh) * 2017-11-14 2020-08-28 普罗菲姆股份有限公司 用于治疗粘膜感染的乳剂
CN113727724A (zh) * 2018-12-17 2021-11-30 乐斯福公司 用于治疗和/或预防口咽念珠菌病的酿酒酵母菌株

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI23311A (sl) * 2010-03-19 2011-09-30 Kemijski inštitut Farmacevtska kombinacija acetilsalicilne kisline in protiglivne substance za uničevanje ali inhibicijo rasti in replikacije gliv
FR2993179B1 (fr) * 2012-07-13 2016-01-08 Lesaffre & Cie Levure saccharomyces cerevisiae pour prevenir et/ou traiter les mycoses vaginales
CN103044408A (zh) * 2013-01-21 2013-04-17 万礼 在治疗恶性肿瘤时应用的伊曲康唑或其盐及其组合物
US8883747B1 (en) * 2013-10-09 2014-11-11 Craig W. Carver Topical antifungal compositions and methods of use thereof
CN104920360B (zh) * 2015-06-18 2017-04-12 青岛农业大学 丁苯羟酸在制备用于防治由植物病原菌引起的植物病害的杀菌剂中的用途
EP3482744A1 (de) 2017-11-14 2019-05-15 ProFem GmbH Emulsionen zur topischen behandlung urogenitaler und dermaler infektionen
EP3482743A1 (de) 2017-11-14 2019-05-15 ProFem GmbH Emulsionen zur behandlung von scheideninfektionen
US20250302821A1 (en) * 2022-05-12 2025-10-02 St. Jude Children's Research Hospital, Inc. Synergistic antifungal composition and method
WO2024187210A1 (de) 2023-03-15 2024-09-19 Profem Gmbh Kombinationsarzneimittel zur behandlung und reduktion der rückfallraten vaginaler mykosen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6471823A (en) * 1987-09-12 1989-03-16 Rohto Pharma Sustained remedy for vaginal candidiasis
US5087620A (en) * 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
EP0735861A1 (en) * 1993-12-23 1996-10-09 The Procter & Gamble Company Tissue moisturizing and antimicrobial compositions
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
WO2000048633A1 (en) 1999-02-19 2000-08-24 Ligocyte Pharmaceuticals, Inc. Antibodies against hydrophobic proteins that are protective against candidiasis
EP1191939B1 (en) * 1999-03-24 2007-10-17 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
GB0108082D0 (en) 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20040142910A1 (en) * 2002-10-21 2004-07-22 Aegis Biosciences Llc Sulfonated styrene copolymers for medical uses
WO2004060283A2 (en) * 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
JPWO2005000287A1 (ja) 2003-06-25 2006-10-05 久光製薬株式会社 水虫治療用外用剤
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
TWI290051B (en) 2004-05-28 2007-11-21 Schering Corp Particulate-stabilized injectable pharmaceutical compositions of Posaconazole

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210649A (zh) * 2010-04-09 2011-10-12 上海医药科技发展有限公司 一种两性霉素b乳膏及其制备方法
CN107106690A (zh) * 2015-01-13 2017-08-29 方济各安吉利克化学联合股份有限公司 用于治疗真菌病的药物组合物
CN111601585A (zh) * 2017-11-14 2020-08-28 普罗菲姆股份有限公司 用于治疗粘膜感染的乳剂
CN111601585B (zh) * 2017-11-14 2023-10-13 普罗菲姆股份有限公司 用于治疗粘膜感染的乳剂
CN113727724A (zh) * 2018-12-17 2021-11-30 乐斯福公司 用于治疗和/或预防口咽念珠菌病的酿酒酵母菌株

Also Published As

Publication number Publication date
EP3192507B1 (de) 2020-07-08
CA2651726A1 (en) 2007-11-22
RS56044B1 (sr) 2017-09-29
HUE033499T2 (en) 2017-12-28
SI2018164T1 (sl) 2017-07-31
US20090208558A1 (en) 2009-08-20
JP2009536926A (ja) 2009-10-22
WO2007131253A2 (de) 2007-11-22
RU2008148977A (ru) 2010-06-20
AU2007250502B2 (en) 2013-11-28
AU2007250502A1 (en) 2007-11-22
DK2018164T3 (en) 2017-06-12
US8815925B2 (en) 2014-08-26
NO20085181L (no) 2009-02-10
PL2018164T3 (pl) 2017-08-31
CY1119094T1 (el) 2018-01-10
LT2018164T (lt) 2017-07-10
EP3192507A1 (de) 2017-07-19
ES2627268T3 (es) 2017-07-27
EP2018164A2 (de) 2009-01-28
NO20180083A1 (no) 2009-02-10
PT2018164T (pt) 2017-06-12
NO342103B1 (no) 2018-03-26
HRP20170793T1 (hr) 2017-10-06
NO345064B1 (no) 2020-09-14
EP2018164B1 (de) 2017-03-01
CA2651726C (en) 2015-12-15
WO2007131253A3 (de) 2008-11-27
US8552042B2 (en) 2013-10-08
US20140030312A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CN101484162A (zh) 包含抗真菌试剂的组合制剂的用途
Ray et al. Topical antimicrobial therapy: Current status and challenges
AU2010212634B2 (en) Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases
das Neves et al. Local treatment of vulvovaginal candidosis: general and practical considerations
Samaranayake et al. Delivery of antifungal agents to the oral cavity
WO2007096931A2 (en) Use of piperacillin in topical intravaginal preparations for the treatment of vaginal bacterial infections
JP2021503002A (ja) 皮膚および粘膜感染症の局所治療用エマルション
KR101235370B1 (ko) 질염 증상완화용 세정제 조성물 및 그것을 포함하는 질 세정용 키트
CN109069413B (zh) 用于治疗阴道真菌感染的葡萄糖酸δ-内酯
US20150164837A1 (en) Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
MD4802C1 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
AU2017261517B2 (en) Use of combination preparations, comprising antimycotics
OLTEAN MANAGEMENT OF MUCOCUTANEOUS CANDIDIASIS
RU2262948C1 (ru) Способ лечения кандидозного вульвовагинита у беременных
UA18589U (en) Method for preventing and treating inflammatory complications after embolization of uterine arteries in patients with leiomyoma uteri
BR112018070370B1 (pt) Glucono delta-lactona para tratamento de candidíase vulvovaginal
MXPA06008279A (en) Fluconazole-tinidazole combination for the treatment of vaginal infections, composition thereof and preparation and use of same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090715